Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors

Abstract This study analyzed whether extended molecular profiling can predict the development of epidermal growth factor receptor (EGFR) gene T790M mutation, which is the most frequent resistance alteration in non‐small cell lung cancer (NSCLC) after treatment with the first‐/second‐generation (1G/2...

Full description

Bibliographic Details
Main Authors: Michael Menzel, Martina Kirchner, Klaus Kluck, Markus Ball, Susanne Beck, Michael Allgäuer, Christin Assmann, Johannes Schnorbach, Anna‐Lena Volckmar, Timothy Kwang Yong Tay, Hannah Goldschmid, Daniel SW Tan, Michael Thomas, Daniel Kazdal, Jan Budczies, Albrecht Stenzinger, Petros Christopoulos
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:The Journal of Pathology: Clinical Research
Subjects:
non‐small cell lung cancer (NSCLC)
epidermal growth factor receptor (EGFR)
T790M mutation
whole exome sequencing (WES)
tyrosine kinase inhibitor
tumor heterogeneity
Online Access:https://doi.org/10.1002/cjp2.354

Internet

https://doi.org/10.1002/cjp2.354

Similar Items